The United Kingdom and the United States have forged a significant trade agreement that will preserve no import taxes on UK medicine exports being sold in the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase funding on drugs through the public health system. This move ensures that import taxes on these key exports will be held at nothing for a duration of three years.
This deal follows recent statements to hike tariffs on branded pharmaceutical products, with increases discussed up to double the cost.
"This arrangement with the UK strengthens the international landscape for cutting-edge drugs and establishes much-needed equity to transatlantic pharmaceutical trade," a statement declared.
Economic Impact
Pharmaceuticals represent one of the Britain's largest export categories to the United States, which is clearly the largest buyer for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period to the end of the third quarter, the UK shipped drugs totaling billions to the US. This figure accounted for 17.4% of British export trade in that period.
"This guarantee secures work, increases investment and facilitates the UK to establish itself as a worldwide center for medical research," a minister remarked.
Key British Pledges
The agreement includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase overall NHS spending on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates exceeded twenty percent.
Broader Context
This agreement takes place against a protracted tension between the pharmaceutical industry and the ministers over spending levels and approval rates.
These tensions were exacerbated by arguments that US patients were paying significantly more for the same drugs than consumers in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while major investments have been announced toward American operations.
One official acknowledged that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a share of its total funding over the previous ten-year period.
